Phase I/Ib Study of Sarasar [lonafarnib] and Temodar [temozolomide] in Patients With Recurrent or Temodar-Refractory Glioblastoma Multiforme

Trial Profile

Phase I/Ib Study of Sarasar [lonafarnib] and Temodar [temozolomide] in Patients With Recurrent or Temodar-Refractory Glioblastoma Multiforme

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Lonafarnib (Primary) ; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 07 Jun 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 01 Mar 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top